Metabolic Health
Conditions
Keywords
cherry consumption, metabolic health, phenolic compounds
Brief summary
This study is designed to evaluate the effects of daily sweet cherry consumption on markers of metabolic health in adults. Cherries are rich in bioactive compounds, such as anthocyanins and phenolic acids, which may help reduce oxidative stress, inflammation, and early risk factors for conditions like type 2 diabetes and cardiovascular disease. Participants will consume 280 grams of fresh sweet cherries every day for 42 consecutive days. Blood and urine samples will be collected at four time points: before the intervention (baseline), at day 21, at day 42 (end of the intervention), and two weeks after stopping cherry consumption. The study will measure changes in blood sugar regulation, markers of inflammation, oxidative stress, liver and kidney function, and immune response. Waist circumference and body mass index will also be recorded. The aim of this study is to test whether daily cherry consumption can support metabolic health in healthy adults and to provide data that may inform larger and longer clinical trials in the future.
Interventions
DIETARY_SUPPLEMENTSweet cherries, 280 g daily for 42 days
Participants will consume 280 grams of fresh sweet cherries daily for 42 consecutive days. Cherries are provided in pre-weighed portions to be consumed in the morning on an empty stomach
Sponsors
Instituto Politécnico da Guarda
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
* Age 18-65 years old * Healthy individuals with no known metaboli disorders
Exclusion criteria
* Alcohol consumption * Smoking * Adverse or allergic reaction to cherries * Use of antibiotics, anxiolytics, or dietary supplements * Pregnancy or lactation * Weight changes greater than 10% in the previous year.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes in fasting glucose | Baseline, Day 21, Day 42 and 2 weeks post-intervention |
| Changes in HbA1c | Baseline, Day 21, Day 42 and 2 weeks post-intervention |
| Changes in estimated average glucose | Baseline, Day 21, Day 42 and 2 weeks post-intervention |
| Changes in insulin | Baseline, Day 21, Day 42 and 2 weeks post-intervention |
| Changes in IL-6 | Baseline, Day 21, Day 42 and 2 weeks post-intervention |
| Changes in AGP-1 | Baseline, Day 21, Day 42 and 2 weeks post-intervention |
| Changes in C-reactive protein | Baseline, Day 21, Day 42 and 2 weeks post-intervention |
| Changes in gluthatione peroxidase | Baseline, Day 21, Day 42 and 2 weeks post-intervention |
| Changes in gluthatione reductase | Baseline, Day 21, Day 42 and 2 weeks post-intervention |
| Changes in glutamate dehydrogenase | Baseline, Day 21, Day 42 and 2 weeks post-intervention |
Secondary
| Measure | Time frame |
|---|---|
| Changes in lactate dehydrogenase | Baseline, Day 21, Day 42 and 2 weeks post-intervention |
| Changes in total proteins | Baseline, Day 21, Day 42 and 2 weeks post-intervention |
| Changes in albumin | Baseline, Day 21, Day 42 and 2 weeks post-intervention |
| Changes in urea | Baseline, Day 21, Day 42 and 2 weeks post-intervention |
| Changes in TIBC | Baseline, Day 21, Day 42 and 2 weeks post-intervention |
| Changes in transferrin | Baseline, Day 21, Day 42 and 2 weeks post-intervention |
| Changes in ferritin | Baseline, Day 21, Day 42 and 2 weeks post-intervention |
| Changes in amylase | Baseline, Day 21, Day 42 and 2 weeks post-intervention |
| Changes in lipase | Baseline, Day 21, Day 42 and 2 weeks post-intervention |
| Changes in IgA | Baseline, Day 21, Day 42 and 2 weeks post-intervention |
| Changes in IgG | Baseline, Day 21, Day 42 and 2 weeks post-intervention |
| Changes in IgM | Baseline, Day 21, Day 42 and 2 weeks post-intervention |
| Changes in total IgE | Baseline, Day 21, Day 42 and 2 weeks post-intervention |
| Changes in rheumatoid factor | Baseline, Day 21, Day 42 and 2 weeks post-intervention |
| Changes in antistreptolysin O | Baseline, Day 21, Day 42 and 2 weeks post-intervention |
| Changes in creatinine | Baseline, Day 21, Day 42 and 2 weeks post-intervention |
| Changes in total cholesterol | Baseline, Day 21, Day 42 and 2 weeks post-intervention |
| Changes in HDL cholesterol | Baseline, Day 21, Day 42 and 2 weeks post-intervention |
| Changes in LDL cholesterol | Baseline, Day 21, Day 42 and 2 weeks post-intervention |
| Changes in waist circumference | Baseline and Day 42 |
| Body Mass Index | Baseline and Day 42 |
| Changes in triglycerides | Baseline, Day 21, Day 42 and 2 weeks post-intervention |
| Changes in microalbumin | Baseline, Day 21, Day 42 and 2 weeks post-intervention |
| Changes in uric acid | Baseline, Day 21, Day 42 and 2 weeks post-intervention |
| Changes in iron | Baseline, Day 21, Day 42 and 2 weeks post-intervention |
| Changes in aspartate aminotransferase | Baseline, Day 21, Day 42 and 2 weeks post-intervention |
| Changes in alanine transaminase | Baseline, Day 21, Day 42 and 2 weeks post-intervention |
| Changes in gamma-glutamyl transferase | Baseline, Day 21, Day 42 and 2 weeks post-intervention |
| Changes in total bilirubin | Baseline, Day 21, Day 42 and 2 weeks post-intervention |
| Changes in conjugated bilirubin | Baseline, Day 21, Day 42 and 2 weeks post-intervention |
| Changes in unconjugated bilirubin | Baseline, Day 21, Day 42 and 2 weeks post-intervention |
Countries
Portugal
Outcome results
None listed